Hicham Skali

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5090733/hicham-skali-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124
papers7,182
citations42
h-index83
g-index158
ext. papers8,632
ext. citations7.7
avg, IF5.29
L-index

#	Paper	IF	Citations
124	Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure Journal of the American College of Cardiology, 2022, 79, 355-368	15.1	1
123	Cardiac Structure and Function and Diabetes-Related Risk of Death or Heart Failure in Older Adults <i>Journal of the American Heart Association</i> , 2022 , e022308	6	1
122	Association of Left Atrial Structure and Function With Heart Failure in Older Adults <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1549-1561	15.1	1
121	Update on guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: Emphasis on transition to chronic endemic state. An information statement from ASNC, IAEA, and SNMMI <i>Journal of Nuclear Cardiology</i> , 2022 , 1	2.1	0
120	Reducing radiation dose from myocardial perfusion imaging in subjects with complex congenital heart disease. <i>Journal of Nuclear Cardiology</i> , 2021 , 28, 1395-1408	2.1	6
119	Coronary vasomotor dysfunction portends worse outcomes in patients with breast cancer. <i>Journal of Nuclear Cardiology</i> , 2021 , 1	2.1	1
118	Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late Life. <i>Journal of the American Heart Association</i> , 2021 , 10, e020094	6	1
117	High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Clinical Chemistry</i> , 2021 , 67, 298-307	5.5	2
116	Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life. <i>JAMA Cardiology</i> , 2021 , 6, 509-520	16.2	7
115	Appropriateness of inpatient stress testing: Implications for development of clinical decision support mechanisms and future criteria. <i>Journal of Nuclear Cardiology</i> , 2021 , 28, 1988-1997	2.1	6
114	Absolute Quantitation of Cardiac Tc-Pyrophosphate Using Cadmium-Zinc-Telluride-Based SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 716-722	8.9	13
113	Role of Exercise Treadmill Testing in he Assessment of Coronary Microvascular Disease. <i>JACC: Cardiovascular Imaging</i> , 2021 , 15, 312-312	8.4	1
112	Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI. <i>Journal of Nuclear Cardiology</i> , 2020 , 27, 1022-1029	2.1	22
111	Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. <i>Hypertension</i> , 2020 , 76, 808-818	8.5	5
110	Association of pulmonary hypertension and right ventricular function with exercise capacity in heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 1635-1644	3.7	7
109	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020 , 22, 1133-1143	12.3	8
108	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis. <i>PLoS Medicine</i> , 2020 , 17, e1003361	11.6	3

(2019-2020)

107	Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI. <i>Journal of Nuclear Medicine</i> , 2020 ,	8.9	8
106	Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment. <i>Circulation</i> , 2020 , 141, 21-33	16.7	25
105	Guidance and best practices for reestablishment of non-emergent care in nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An information statement from ASNC, IAEA, and SNMMI: Endorsed by the Infectious Diseases Society of America. <i>Journal of</i>	2.1	16
104	Nuclear Cardiology, 2020 , 27, 1855-1862 Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial <i>Kidney360</i> , 2020 , 1, 1380-1389	1.8	О
103	Guidance and Best Practices for Nuclear Cardiology Laboratories During the COVID-19 Pandemic: An Information Statement From ASNC and SNMMI. <i>Circulation: Cardiovascular Imaging</i> , 2020 , 13, e01176	5₹·9	6
102	Guidance and Best Practices for Reestablishment of Non-Emergent Care in Nuclear Cardiology Laboratories During the Coronavirus Disease 2019 (COVID-19) Pandemic: An Information Statement from ASNC, IAEA, and SNMMI. <i>Journal of Nuclear Medicine Technology</i> , 2020 , 61, 1534-1539	1.1	7
101	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		
100	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		
99	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		
98	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		
97	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		
96	Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. <i>JAMA Cardiology</i> , 2019 , 4, 997-1006	16.2	20
95	Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction: A Cross-sectional Analysis From the ARIC Study. <i>JAMA Network Open</i> , 2019 , 2, e195321	10.4	8
94	Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. <i>Circulation: Cardiovascular Imaging</i> , 2019 , 12, e008975	3.9	18
93	Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT. <i>Radiology</i> , 2019 , 291, 330-337	20.5	19
92	Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy. Heart, 2019 , 105, 34-41	5.1	19
91	Stress Myocardial Perfusion PET Provides Incremental Risk Prediction in Patients with and Patients without Diabetes. <i>Radiology: Cardiothoracic Imaging</i> , 2019 , 1, e180018	8.3	2
90	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. <i>Kidney International</i> , 2019 , 95, 973-982	9.9	44

89	Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis. <i>Circulation: Cardiovascular Imaging</i> , 2018 , 11, e007030	3.9	112
88	Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. <i>JAMA Cardiology</i> , 2018 , 3, 200-206	16.2	28
87	Widening Racial Differences in Risks for Coronary Heart Disease. Circulation, 2018, 137, 1195-1197	16.7	11
86	Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. <i>Journal of Nuclear Cardiology</i> , 2018 , 25, 1136-1146	2.1	72
85	Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage. <i>Kidney International</i> , 2018 , 93, 501-509	9.9	36
84	Resting Heart Rate and Chronotropic Response to Exercise: Prognostic Implications in Heart Failure Across the Left Ventricular Ejection Fraction Spectrum. <i>Journal of Cardiac Failure</i> , 2018 , 24, 753-762	3.3	7
83	Racial Disparities in Risks of Stroke. New England Journal of Medicine, 2017, 376, 2089-2090	59.2	12
82	Kidney Disease Measures and Left Ventricular Structure and Function: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	19
81	Cardiovascular Dysfunction and Frailty Among Older Adults in the Community: The ARIC Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 958-964	6.4	43
80	Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	55
79	Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. <i>Journal of Nuclear Cardiology</i> , 2017 , 24, 86-99	2.1	110
78	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemiathe Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Journal of Human Hypertension, 2016 , 30, 46-52	2.6	9
77	Cardiac Troponin: Myocardial Infarction and More. Hospital Medicine Clinics, 2016, 5, 492-506		
76	Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT. <i>Journal of Cardiovascular Translational Research</i> , 2016 , 9, 421-4	12 8 :3	21
75	Persistently High Cardiac Troponin T with a Negative Cardiac Workup. Clinical Chemistry, 2016 , 62, 896	-7 _{5.5}	
74	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016 , 1, 93-100	5.6	
73	Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Diabetes Care</i> , 2016 , 39, 677-85	14.6	32
72	Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. <i>European Heart Journal</i> , 2016 , 37, 466-72	9.5	22

71	Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes. <i>Circulation: Heart Failure</i> , 2016 , 9, e002826	7.6	62
70	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2015 , 17, 301-12	12.3	37
69	Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	35
68	Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. <i>Circulation: Heart Failure</i> , 2015 , 8, 448-54	7.6	47
67	Approaches to reducing radiation dose from radionuclide myocardial perfusion imaging. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 592-9	8.9	31
66	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , 2015 , 36, 669-75	9.5	47
65	Response to Letter Regarding Article, Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study (Circulation: Heart Failure, 2015, 8, 1010)	7.6	
64	Prognostic value of coronary CTA vs. exercise treadmill testing: results from the Partners registry. <i>European Heart Journal Cardiovascular Imaging</i> , 2015 , 16, 1338-46	4.1	13
63	Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the Atherosclerosis Risk in Communities (ARIC) study. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 550-8	7·4	12
62	Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 329-36	15.1	405
61	Yield of downstream tests after exercise treadmill testing: a prospective cohort study. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1264-1274	15.1	38
60	Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2014 , 130, 820-8	16.7	100
59	Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities). <i>JACC: Heart Failure</i> , 2014 , 2, 447-54	7.9	32
58	Reduction in II -fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. <i>Journal of Nuclear Cardiology</i> , 2014 , 21, 166-74	2.1	168
57	Comparison of the use of downstream tests after exercise treadmill testing by cardiologists versus noncardiologists. <i>American Journal of Cardiology</i> , 2014 , 114, 305-11	3	2
56	Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2380-5	2.2	327
55	Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. <i>European Journal of Heart Failure</i> , 2014 , 16, 560-5	12.3	41
54	Rationale and design of a multicenter echocardiographic study to assess the relationship between cardiac structure and function and heart failure risk in a biracial cohort of community-dwelling elderly persons: the Atherosclerosis Risk in Communities study. <i>Circulation: Cardiovascular Imaging</i> ,	3.9	83

53	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014 , 2, e000011	4.5	21
52	Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2014 , 33, 372-81	5.8	19
51	18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis. <i>Current Cardiology Reports</i> , 2013 , 15, 1	4.2	79
50	Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. <i>American Journal of Kidney Diseases</i> , 2013 , 61, 238-46	7.4	15
49	Detection of obstructive coronary artery disease using regadenoson stress and 82Rb PET/CT myocardial perfusion imaging. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1748-54	8.9	31
48	Differential influence of distinct components of increased blood pressure on cardiovascular outcomes: from the atherosclerosis risk in communities study. <i>Hypertension</i> , 2013 , 62, 492-8	8.5	9
47	18F-FDG PET/CT for the assessment of myocardial sarcoidosis. <i>Current Cardiology Reports</i> , 2013 , 15, 35	24.2	15
46	(18)F-FDG PET/CT for the assessment of myocardial sarcoidosis. <i>Current Cardiology Reports</i> , 2013 , 15, 352	4.2	23
45	Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. European Journal of Heart Failure, 2012, 14, 185-92	12.3	33
44	Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1785-95	15.1	119
43	Anatomical distribution of traumatic pneumothoraces on chest computed tomography: implications for ultrasound screening in the ED. <i>American Journal of Emergency Medicine</i> , 2012 , 30, 102	5 -3 9	11
42	Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test. <i>Journal of Nuclear Cardiology</i> , 2012 , 19, 970-8	2.1	21
41	Correlative imaging of spontaneous coronary artery dissection. <i>Journal of Nuclear Cardiology</i> , 2012 , 19, 625-9	2.1	1
40	Mortality rates in trials of subjects with type 2 diabetes. <i>Journal of the American Heart Association</i> , 2012 , 1, 8-15	6	54
39	Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. <i>American Heart Journal</i> , 2011 , 161, 1156-62	4.9	10
38	Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. <i>American Heart Journal</i> , 2011 , 162, 548-54	4.9	126
37	Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. <i>American Heart Journal</i> , 2011 , 162, 685-91	4.9	26
36	Reducing infarct size with EPO in patients with ST-segment elevation myocardial infarction. American Journal of Kidney Diseases, 2011, 58, 876-8	7.4	

(2006-2011)

35	Novel techniques for assessment of left ventricular systolic function. <i>Heart Failure Reviews</i> , 2011 , 16, 327-37	5	8
34	Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. <i>Circulation</i> , 2011 , 124, 2903-8	16.7	68
33	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. <i>European Heart Journal</i> , 2011 , 32, 1227-34	9.5	114
32	Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. <i>Circulation</i> , 2010 , 122, 597-602	16.7	148
31	Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. <i>European Heart Journal</i> , 2010 , 31, 1088-97	9.5	49
30	Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. <i>JACC: Cardiovascular Imaging</i> , 2008 , 1, 582-91	8.4	172
29	High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. <i>American Heart Journal</i> , 2008 , 155, 706-11	4.9	21
28	Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). <i>American Journal of Cardiology</i> , 2008 , 101, 607-12	3	158
27	Computed tomography-fluoroscopy overlay evaluation during catheter ablation of left atrial arrhythmia. <i>Europace</i> , 2008 , 10, 931-8	3.9	74
26	Marantic endocarditis and disseminated intravascular coagulation with systemic emboli in presentation of pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1383-5	2.2	21
25	Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. <i>Heart Rhythm</i> , 2007 , 4, 308-13	6.7	17
24	Two-dimensional assessment of right ventricular function: an echocardiographic-MRI correlative study. <i>Echocardiography</i> , 2007 , 24, 452-6	1.5	279
23	Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , 2007 , 116, 627-36	16.7	264
22	Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. <i>European Heart Journal</i> , 2007 , 28, 326-33	9.5	72
21	Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. <i>Circulation</i> , 2007 , 116, 1482-7	16.7	400
20	Variable impact of combining fatal and nonfatal end points in heart failure trials. <i>Circulation</i> , 2006 , 114, 2298-303	16.7	29
19	Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 2886-91	12.7	146
18	Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study. <i>Journal of the American Society of Echocardiography</i> ,	5.8	42

17	Risk assessment in patients with depressed left ventricular function after myocardial infarction using the myocardial performance indexSurvival and Ventricular Enlargement (SAVE) experience. Journal of the American Society of Echocardiography, 2006 , 19, 28-33	5.8	14
16	Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. <i>Heart Rhythm</i> , 2006 , 3, 313-6	6.7	45
15	Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 1725-7	15.1	17
14	Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. <i>American Heart Journal</i> , 2005 , 150, 257-62	4.9	41
13	Prognostic use of echocardiography 1 year after a myocardial infarction. <i>American Heart Journal</i> , 2005 , 150, 743-9	4.9	20
12	Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. <i>American Journal of Cardiology</i> , 2005 , 96, 303-5	3	120
11	Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. <i>Circulation</i> , 2005 , 112, 3738-44	16.7	540
10	Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. <i>Circulation</i> , 2005 , 111, 3411-9	16.7	207
9	Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , 2004 , 110, 2180-3	16.7	203
8	Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. <i>Circulation</i> , 2004 , 110, 3667-73	16.7	158
7	Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. <i>Archives of Internal Medicine</i> , 2004 , 164, 2273-9		109
6	Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. <i>Circulation</i> , 2004 , 110, 1572-8	16.7	167
5	Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 2015-21	15.1	60
4	Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. <i>Circulation</i> , 2002 , 106, 1251-5	16.7	81
3	Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. Journal of the American College of Cardiology, 2002 , 39, 1450-5	15.1	334
2	Are we asking too much of our trials?. American Heart Journal, 2002, 143, 1-3	4.9	5
1	Prospects for ARB in the next five years. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone</i> System, 2001 , 2, 215-8	3	4